In the news on the Biotech Segment, stocks remained majorly volatile. With the news in the biotech market segment being dominated by the likes of Abbvie (ABBV), who is trying to acquire Ireland-based Shire (SHPG), we take a look at the other stocks which were in the news and are looking positive: Amgen & Alexion….
Morningstar’s credit rating of BBB+ for Royal Bank of Scotland reflects the bank’s large balance of nonperforming loans but is bolstered by the recent improvements in the bank’s operating performance. Through acquisitions, Royal Bank of Scotland has become a global bank, with operations in 50 countries. RBS is primarily a business bank and is dominated…
Here we take a close look at two upcoming Biotech Stocks which have dominated majority of the news in the Biotech Segment. Xtandi could very well be a game-changer for Medivation. Vivus posted extremely postive results off late but there are reasons to worry if you are an investor of Vivus. Let’s take a closer…
Here we take a close look at three upcoming Biotech Stocks which have dominated majority of the news in the Biotech Segment. All three stocks: Clovis, Biogen & Halozyme have shown some promise in the past and would hope to continue their run of form in the coming months. Let’s take a closer look at…
Here we take a close look at three upcoming Biotech Stocks which have dominated majority of the news in the Biotech Segment. While Sarepta has shown mediocre results in the past few weeks, the stock may be looking for a comeback in the coming times. On the other hand, both Regeneron and Ariad are looking…
AbbVie’s (ABBV) efforts to acquire Ireland-based Shire (SHPG) remains the top news in the biotech market segment. Meanwhile, Gilead Sciences Inc’s (GILD) hepatitis C drug made it to the news yet again thanks to its price tag. Also making it to the news is Clegene Corp. Let’s take a closer look at the three stocks….
